Aliskiren, an Oral Renin Inhibitor, Provides Dose-Dependent Efficacy and Sustained 24-Hour Blood Pressure Control in Patients With Hypertension
Byung-Hee Oh, MD, PhD, FACC*,
Jerry Mitchell, MD, PhD , ,
James R. Herron, MD ,
Jenny Chung, PharmD||,a,
Mahmudul Khan, PhD||,a and
Deborah L. Keefe, MD, MPH, FACC||,a,*
* Seoul National University Hospital, Seoul, Korea
Texas Center for Drug Development, Houston, Texas
Baylor College of Medicine, Houston, Texas
James R. Herron, MD, Ltd., Chicago, Illinois
|| Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
View larger version (25K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Patient Flow
*One patient was randomized to aliskiren 300 mg but did not have any baseline or post-baseline evaluations and was not included in numbers completing or discontinuing.
|
|
View larger version (34K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Effects of Aliskiren, 150 to 600 mg, and Placebo on Blood Pressure in Patients With Mild-to-Moderate Hypertension
(A) Change from baseline to week 8 in mean sitting diastolic blood pressure (msDBP) and mean sitting systolic blood pressure (msSBP). Closed bars = msSBP; open bars = msDBP. (B) Changes in msDBP during double-blind treatment and withdrawal period. (C) Change from baseline in mean ambulatory diastolic blood pressure (DBP) over 24 h.
|
|
|
